When “No Options” Starts to Change: A New Chapter for Seronegative Myasthenia Gravis

For many people living with generalized myasthenia gravis (gMG), the journey is not just defined by symptoms—it’s shaped by uncertainty. Uncertainty in diagnosis. Uncertainty in treatment. And for a significant subset of the community, uncertainty in whether therapies designed for others will work for them at all.

That’s why moments like this matter.

The recent decision by the U.S. Food and Drug Administration (FDA) to expand approval of VYVGART^® (efgartigimod alfa-fcab) and VYVGART Hytrulo^® (efgartigimod alfa and hyaluronidase-qvfc)  to include all adults living with generalized myasthenia gravis (gMG), regardless of serotype, represents more than a regulatory milestone—it signals a shift in who gets to be seen, studied, and served in rare disease care.

The Reality of Being “Seronegative”

In a condition already considered rare, being seronegative can feel like living in an even smaller, quieter corner of the room. Approximately 20% of people with gMG do not test positive for the most common antibody (AChR), which has historically made both diagnosis and treatment more complex.

These individuals—some with MuSK or LRP4 antibodies, others with no identifiable antibodies at all—have often navigated a landscape where clinical trials excluded them and treatment decisions relied heavily on extrapolation rather than evidence.

In other words: they’ve been asked to trust a system that didn’t always include them.

Why This Approval Feels Different

This expansion is meaningful because it directly addresses that gap. The Phase 3 ADAPT SERON trial demonstrated measurable improvements in daily living activities for people with seronegative gMG—across subgroups that have historically been underrepresented in research.

That matters in very real, human terms.

It means more than a data point—it means the potential to:

• Speak more clearly in a conversation
• Swallow without fear
• Move through the day with greater strength and less fatigue

It means reclaiming pieces of independence that this disease can quietly take.

A Signal of Progress—And Inclusion

At its core, this moment reflects something bigger than one therapy: it reflects progress toward a more inclusive research and care ecosystem.

For organizations like the Muscular Dystrophy Association (MDA), which has long supported multidisciplinary care and invested more than $57 million into myasthenia gravis research, this kind of advancement underscores the importance of persistence—of continuing to push until every segment of a community is represented.

Because progress isn’t just about breakthroughs. It’s about who those breakthroughs reach.

Hope, Backed by Evidence

For individuals like Carol Alvarez, an MDA Ambassador living with myasthenia gravis, this approval carries emotional weight:

“Hearing that the FDA has approved a therapy specifically studied in people living with MG gives our community hope that we are being seen and that progress is continuing.”

Hope, in this context, is not abstract. It’s grounded in recognition. In validation. In finally being included in the conversation.

What Comes Next

This milestone doesn’t mark the finish line—it marks momentum.

There is still work to be done:

• Ensuring equitable access to therapies
• Continuing to expand research across all subtypes
• Supporting individuals through the complexities of care, insurance, and long-term management

But it also reinforces something important: the system can evolve.

And when it does, it has the power to change not just treatment pathways—but lived experiences.

The Bigger Picture

For those outside the gMG community, this moment may seem like a niche advancement. But for those living it, it represents a widening of possibility.

A reminder that even in rare disease spaces—especially in rare disease spaces—progress is not just about innovation.

It’s about inclusion.
It’s about persistence.
And ultimately, it’s about people.